Gabriel Kristian Pedersen

Research

My research aims at getting a better understanding of how vaccine adjuvants can be used to optimally protect against different disease targets. This includes:

• Mechanistic studies of how vaccine adjuvants work
• Developing novel adjuvants
• Comparing adjuvants in various settings to understand which adjuvants are best suited for protecting against various pathogens and in cancer vaccines

Responsibilities

• Head of Adjuvant Research, Center for Vaccine Research

Publications

• Christensen D, Polacek C, Sheward DJ, Hanke L, Morro AM, McInerney G, Murrell B, Hartmann KT, Elvang Jensen H, Jungersen G, Illigen K, Isling LK, Jensen RF, Hansen JS, Rosenkrands I, Fernandez-Antunez C,  Ramirez S,  Follmann F, Bukh J, Pedersen GK. Protection against SARS-CoV-2 Transmission by a Parenteral Prime - Intranasal Boost Vaccine Strategy. eBioMedicine 2022 (in press)
• Van Haren SD*, Pedersen GK*, Kumar A, Ruckwardt TJ, Moin S, Moore IN, Minai M, Liu M, Pak J, Borriello F, Doss-Gollin S, Beijnen EMS, Ahmed S, Helmel M, Andersen P, Graham BS, Steen H, Christensen D, Levy O. CAF08 adjuvant enables single dose protection against respiratory syncytial virus infection in murine newborns. Nat Comm 2022 (in press)
• Wørzner K, Sheward DJ, Schmidt ST, Hanke L, Zimmermann J, McInerney G, Karlsson Hedestam GB, Murrell B, Christensen D, Pedersen GK. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. EBioMedicine 2021;63:103197.
• Pedersen GK, Andersen P, Christensen D. 2018. Immunocorrelates of CAF family adjuvants. Semin Immunol 39: 4-13
• Pedersen GK, Àdori M, Khoenkhoen S, Dosenovic P, Beutler B, Karlsson Hedestam GB. 2014. B-1a transitional cells are phenotypically distinct and are lacking in mice deficient in IκBNS. PNAS 111:E4119-26